JP2019534710A5 - - Google Patents

Download PDF

Info

Publication number
JP2019534710A5
JP2019534710A5 JP2019538102A JP2019538102A JP2019534710A5 JP 2019534710 A5 JP2019534710 A5 JP 2019534710A5 JP 2019538102 A JP2019538102 A JP 2019538102A JP 2019538102 A JP2019538102 A JP 2019538102A JP 2019534710 A5 JP2019534710 A5 JP 2019534710A5
Authority
JP
Japan
Prior art keywords
antibody
amino acid
seq
set forth
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019538102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534710A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/053880 external-priority patent/WO2018064255A2/en
Publication of JP2019534710A publication Critical patent/JP2019534710A/ja
Publication of JP2019534710A5 publication Critical patent/JP2019534710A5/ja
Priority to JP2022105725A priority Critical patent/JP2022141693A/ja
Pending legal-status Critical Current

Links

Images

JP2019538102A 2016-09-28 2017-09-28 インターロイキン2に結合する抗体およびその使用 Pending JP2019534710A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022105725A JP2022141693A (ja) 2016-09-28 2022-06-30 インターロイキン2に結合する抗体およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662401158P 2016-09-28 2016-09-28
US62/401,158 2016-09-28
US201662421038P 2016-11-11 2016-11-11
US62/421,038 2016-11-11
PCT/US2017/053880 WO2018064255A2 (en) 2016-09-28 2017-09-28 Antibodies that bind interleukin-2 and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022105725A Division JP2022141693A (ja) 2016-09-28 2022-06-30 インターロイキン2に結合する抗体およびその使用

Publications (2)

Publication Number Publication Date
JP2019534710A JP2019534710A (ja) 2019-12-05
JP2019534710A5 true JP2019534710A5 (enExample) 2020-11-12

Family

ID=60117762

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019538102A Pending JP2019534710A (ja) 2016-09-28 2017-09-28 インターロイキン2に結合する抗体およびその使用
JP2022105725A Pending JP2022141693A (ja) 2016-09-28 2022-06-30 インターロイキン2に結合する抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022105725A Pending JP2022141693A (ja) 2016-09-28 2022-06-30 インターロイキン2に結合する抗体およびその使用

Country Status (13)

Country Link
US (2) US10858428B2 (enExample)
EP (1) EP3518969A2 (enExample)
JP (2) JP2019534710A (enExample)
KR (1) KR20190057113A (enExample)
CN (1) CN110087681A (enExample)
AU (1) AU2017335771A1 (enExample)
BR (1) BR112019005944A2 (enExample)
CA (1) CA3038679A1 (enExample)
IL (1) IL265323A (enExample)
MX (1) MX2019003543A (enExample)
PH (1) PH12019500643A1 (enExample)
WO (1) WO2018064255A2 (enExample)
ZA (1) ZA201901892B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190057113A (ko) * 2016-09-28 2019-05-27 조마 (유에스) 엘엘씨 인터루킨-2에 결합하는 항체 및 그 용도
JP7537766B2 (ja) * 2019-08-09 2024-08-21 国立研究開発法人理化学研究所 人工アジュバントベクター細胞と免疫賦活化剤との併用
CN115397852B (zh) * 2020-02-16 2023-08-11 奥罗斯生物科学公司 工程化抗il-2抗体
CN111499746B (zh) * 2020-04-28 2020-11-24 优睿赛思(武汉)生物科技有限公司 一种针对人白介素-2的高亲和力兔单克隆抗体及其应用
CN114441763A (zh) * 2020-10-30 2022-05-06 江苏恒瑞医药股份有限公司 一种白细胞介素2的检测方法
US20230414720A1 (en) * 2020-11-23 2023-12-28 University Of Florida Research Foundation, Incorporated Use of insulin-like growth factors with gamma-chain cytokines to induce homeostatic proliferation of lymphocytes
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
EP4578871A1 (en) * 2022-08-23 2025-07-02 Mustbio Co., Ltd. Il2 variant and protein complex comprising same
CN115850471A (zh) * 2022-10-13 2023-03-28 深圳市百士通科技开发有限公司 一种抗人il-2单克隆抗体及其应用
CN118440194B (zh) * 2024-05-23 2024-11-26 武汉爱博泰克生物科技有限公司 用于检测鼠白介素-2的抗体、抗体对及检测试剂或试剂盒

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
DK0494955T3 (da) 1989-10-05 1998-10-26 Optein Inc Cellefri syntese og isolering af hidtil ukendte gener og polypeptider
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
ATE269401T1 (de) 1991-04-10 2004-07-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
EP0571613B1 (en) 1991-12-13 2003-09-17 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
WO1993016177A1 (en) 1992-02-11 1993-08-19 Cell Genesys, Inc. Homogenotization of gene-targeting events
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP0652950B1 (en) 1992-07-24 2007-12-19 Amgen Fremont Inc. Generation of xenogeneic antibodies
US6664114B1 (en) 1992-08-03 2003-12-16 Sapidyne Instruments, Inc. Solid phase assay for detection of ligands
CA2145063A1 (en) 1992-09-22 1994-03-31 Cambridge Genetics Limited Recombinant viruses displaying a nonviral polypeptide on their external surface
US6054287A (en) 1994-05-27 2000-04-25 Methodist Hospital Of Indiana, Inc. Cell-type-specific methods and devices for the low temperature preservation of the cells of an animal species
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
CA2616914C (en) 1996-12-03 2012-05-29 Abgenix, Inc. Egfr-binding antibody
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
WO2002043478A2 (en) 2000-11-30 2002-06-06 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ATE435239T1 (de) 2002-03-29 2009-07-15 Schering Corp Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
EP1888644A1 (en) * 2005-06-01 2008-02-20 Micromet AG Anti-il2 antibodies
CN101208472B (zh) 2005-06-03 2013-01-16 美特索造纸公司 用于木材的机械纤维分离的方法和装置
US20100310501A1 (en) 2006-02-16 2010-12-09 Onur Boyman Methods for Improving Immune Function and Methods for Prevention or Treatment of Disease in a Mammalian Subject
EP2038417A2 (en) 2006-07-06 2009-03-25 Merck Patent GmbH Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
CU23734A1 (es) 2009-11-27 2011-11-15 Centro Inmunologia Molecular Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
CN110812488A (zh) 2010-11-12 2020-02-21 尼克塔治疗公司 Il-2部分与聚合物的缀合物
TWI666027B (zh) 2011-02-10 2019-07-21 羅齊克雷雅公司 突變介白素-2多肽
EA201990698A1 (ru) 2011-06-03 2019-12-30 Ксома Текнолоджи Лтд. Антитела, специфические к tgf-бета
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
WO2014100014A1 (en) 2012-12-17 2014-06-26 The Board Of Trustees Of The Leland Stanford Junior University Super-2 complexes with antibody to augment il-2 therapy
WO2014108748A1 (en) 2013-01-10 2014-07-17 Freescale Semiconductor, Inc. Packet processing architecture and method therefor
WO2015109212A1 (en) * 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
LT3102595T (lt) 2014-02-06 2019-01-25 F. Hoffmann-La Roche Ag Interleukino-2 sulieti baltymai ir jų panaudojimas
CN106659757B (zh) 2014-04-24 2022-01-28 利兰斯坦福初级大学董事会 白介素2的超级激动剂、部分激动剂和拮抗剂
DK3166973T3 (da) 2014-07-10 2020-04-06 Univ Zuerich Immunstimulerende monoklonale antistoffer mod human interleukin-2
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
HUE047806T2 (hu) 2014-08-29 2020-05-28 Hoffmann La Roche Kombinációs kezelés tumort célzó IL-2-variáns immuncitokinekkel és humán PD-L1 elleni antitestekkel
JP7030689B2 (ja) * 2015-10-23 2022-03-07 ファイザー インコーポレイティッド 抗il-2抗体ならびにその組成物及び使用
IL260218B2 (en) * 2016-01-11 2023-04-01 Novartis Ag Humanized monoclonal antibodies that elicit an immune response against interleukin-2, and their fusion proteins
KR20190057113A (ko) * 2016-09-28 2019-05-27 조마 (유에스) 엘엘씨 인터루킨-2에 결합하는 항체 및 그 용도

Similar Documents

Publication Publication Date Title
JP2019534710A5 (enExample)
Strohl Current progress in innovative engineered antibodies
US10561653B2 (en) 5-bromo-2,6-di-(1H-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
CN108348601B (zh) 与lag3结合的抗体治疗剂
JP2025016606A5 (enExample)
BR112020026862A2 (pt) antagonistas antitumorais de reguladores de pontos de verificação imunológica
JP2020520665A5 (enExample)
JP2018505177A5 (enExample)
JP2019502676A5 (enExample)
JP2016507555A5 (enExample)
FI3932951T3 (fi) Menetelmiä ihosyövän hoitamiseksi antamalla PD-1-inhibiittoria
TW201023855A (en) Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
JP2009541492A5 (enExample)
JP2012501626A5 (enExample)
IL292780A (en) A new 4-1bbl trimer containing antigen-binding molecules
US20230227577A1 (en) Anti-dll3 antibodies and methods of use
JP7712925B2 (ja) 腫瘍治療のための二重特異性融合タンパク質と抗Her2抗体の組合せ
US20230312738A1 (en) System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies
BR112019020185A2 (pt) Métodos e composições para redução da imunogenicidade
WO2012154587A2 (en) Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-erbb3 agents
JP2024054123A (ja) 癌の治療のための配合剤
TW202104263A (zh) 雙特異性CD123xCD3雙抗體在血液系統惡性腫瘤治療中的給藥方案
JP2022553129A (ja) ポリオウイルス受容体(pvr)に対する抗体およびその使用
JP2019526244A5 (enExample)
CN119997974A (zh) 一种异源二聚体融合蛋白及其应用